绝经后受体阳性乳腺癌患者高危人群的内分泌治疗

《绝经后受体阳性乳腺癌患者高危人群的内分泌治疗》由会员上传分享，免费在线阅读，更多相关内容在教育资源-天天文库。

1、绝经后激素受体阳性乳腺癌患者高危人群的内分泌治疗北京大学人民医院王殊ER阳性患者预后EBCTCG，Lancet.2005Long-TermRiskofBreastCancerPresentedByIanSmithat2014ASCOAnnualMeetingClinicaltrialsMA17AnastrozoleletrozoleexemetaneBIG1-98ATACABCSG6aIESB33ABCSG-8ARNO95/ITATEAMUpfrontswitch/sequentialextendedMA27ANA5YEXE5YFACEANA5YLET5YHe

2、adtoheadATTOMATLASTamoxifen高危人群肿瘤大小淋巴结转移组织学分级ER/PRHER2Ki67分子分型RSROR淋巴结转移与生存AnnalsofOncology,2007受体阳性乳腺癌患者的生存(SEERData)0.951.000.900.850.800.7501020304050607080Survival(mo)CumulativeproportionsurvivingJointER/PRPhenotypeER+PR+(n=12,811)ER+PR-(n=2,436)ER-PR+(n=663)Node-negativepatient

3、swithT1-T3tumorsHER2阳性患者预后较差TamoxifenAnastrozoleRFSRFSDowsett,JCO,2008Ki-67PatholOncolRes. 20141021-GeneRecurrenceScoreAssayforPostmenopausal,ER(+)BreastCancerLancetOncol.2010高危人群风险控制AI还是TAM?初始还是序贯？5年还是更长？高危人群风险控制AI还是TAM?初始还是序贯？5年还是更长？ATACBIG1-98RelationshipofERlevelandresponsetoE

4、T高危人群风险控制AI还是TAM?初始还是序贯？5年还是更长？BIG1-98序贯高危人群风险控制AI还是TAM?初始还是序贯？5年还是更长？PooledanalysisATLAS+aTTom:
BreastCancerMortalityPresentedByIanSmithat2014ASCOAnnualMeetingExtendedAdjuvantTherapywithAIs

PresentedByIanSmithat2014ASCOAnnualMeetingSlide13PresentedByIanSmithat2014ASCOA

5、nnualMeetingSlide14PresentedByIanSmithat2014ASCOAnnualMeetingLonger-TermOutcomesofLetrozolev.PlaceboAfter5YearsofTamoxifenintheMA.17Trial:
AnalysesAdjustingforTreatmentCrossoverPresentedByIanSmithat2014ASCOAnnualMeetingMA17HR=0.61，P=.04Slide17PresentedByIanSmithat2014ASCOAnnualM

6、eetingSlide19PresentedByIanSmithat2014ASCOAnnualMeetingSlide20PresentedByIanSmithat2014ASCOAnnualMeetingSlide21PresentedByIanSmithat2014ASCOAnnualMeetingHowLongIsLongEnough?
DefiningOptimalDurationandSelectionofAdjuvantEndocrineTherapyPresentedByIanSmithat2014ASCOAnnualMeetingCo

7、nclusion
SoWhatdoWeDoAsClinicians?PresentedByIanSmithat2014ASCOAnnualMeeting副作用-ATAC副作用BIG1-98副作用-IESValue-BasedApproachtoSystemicTherapyinPatientswithBreastCancer:WhatistheEvidence?PresentedByMichaelHassettat2014ASCOAnnualMeetingWhatdowegetforwhatwespend?PresentedByMichaelHasse

8、ttat2014ASCOAnnualM